Word abonnee en neem Beursduivel Premium
Rode planeet als pijlen grid met hoorntjes Beursduivel

Guru Terug naar discussie overzicht

***** GTCB 2007 ******

2.783 Posts
Pagina: «« 1 ... 118 119 120 121 122 ... 140 »» | Laatste | Omlaag ↓
  1. $rob$ 4 september 2007 17:34
    Ik ga er vanuit dat we nu de komende tijd rond de 1,15 zullen blijven, tot er meer nieuws komt....
    rob
  2. [verwijderd] 4 september 2007 17:49
    rekenen ze met 8 maanden goedkeuring fasttrac bij de FDA?

    dan moet PH toch ook snel filen, willen ze eind maart goedkeuring hebben. of zie ik dat verkeerd?

  3. [verwijderd] 4 september 2007 17:52
    GTC Biotherapeutics (GTCB:
    gtc biotherapeutics inc com
    News, chart, profile, more
    Last: 1.16+0.14+13.73%
    10:29am 09/04/2007
    Delayed quote data
    Add to portfolio
    Analyst
    Create alert
    Insider
    Discuss
    Financials
    Sponsored by:
    GTCB1.16, +0.14, +13.7%) was the big mover amongst the small caps, up 15% at $1.17.
    The biotech group said the FDA has granted fast-track status for its drug candidate Atryn, meaning it can submit data for its market application to the agency on a "rolling" basis. GTC is seeking to have Atryn approved to treat hereditary antithrombin deficiency, which can increase the risk of blood clots. End of Story
    Val Brickates Kennedy is a reporter for MarketWatch in Boston.


    FRAMINGHAM, Mass.--(BUSINESS WIRE)--GTC Biotherapeutics, Inc. ("GTC")(Nasdaq:GTCB) announced today that the US Food and Drug Administration, or FDA, has designated ATryn® a “fast track product” entitled to accelerated FDA review for the hereditary antithrombin deficiency indication. The FDA has also granted GTC permission to submit the associated Biologics License Application, or BLA, for ATryn® on a rolling basis. Fast track designation is provided to those products that are intended to treat serious or potentially life threatening conditions for which there is an unmet medical need. The BLA requesting marketing approval for ATryn® will be submitted as sections are completed rather than waiting for all sections to be submitted together, enabling FDA review to begin sooner. GTC anticipates filing the initial sections with the FDA in the fourth quarter and completing the rolling submission after all clinical data is gathered, analyzed, and available for the BLA, which is planned to be by the end of the first quarter of 2008
  4. [verwijderd] 4 september 2007 18:06
    1.12 +0.10 +10.00%

    Previous Close 1.02 Bid/Tick 1.12
    Open 1.14 Bid Size 1,900
    Day's High 1.19 Ask 1.13
    Day's Low 1.12 Ask Size 4,200
    Volume 1.44 Mil 52 Week Range 0.96-1.39

  5. [verwijderd] 4 september 2007 18:24
    ttw....hou de fundamentals en de koers nu is gescheiden.......de koers wordt gewoon gemaakt.......en gaat gewoon weer naar de dollar (volgens mij) dus op tijd er uit en goedkoop er in met een gedeelte de rest hou je lekker vast. die worden vanzelf goedkoper.
2.783 Posts
Pagina: «« 1 ... 118 119 120 121 122 ... 140 »» | Laatste |Omhoog ↑

Neem deel aan de discussie

Word nu gratis lid van Beursduivel.be

Al abonnee? Log in

Direct naar Forum

Zoek alfabetisch op forum

  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z
Forum # Topics # Posts
Aalberts 466 7.017
AB InBev 2 5.496
Abionyx Pharma 2 29
Ablynx 43 13.356
ABN AMRO 1.582 51.649
ABO-Group 1 22
Acacia Pharma 9 24.692
Accell Group 151 4.132
Accentis 2 264
Accsys Technologies 23 10.645
ACCSYS TECHNOLOGIES PLC 218 11.686
Ackermans & van Haaren 1 188
ADMA Biologics 1 34
Adomos 1 126
AdUX 2 457
Adyen 14 17.751
Aedifica 3 916
Aegon 3.258 322.826
AFC Ajax 538 7.088
Affimed NV 2 6.296
ageas 5.844 109.892
Agfa-Gevaert 14 2.050
Ahold 3.538 74.335
Air France - KLM 1.025 35.043
AIRBUS 1 12
Airspray 511 1.258
Akka Technologies 1 18
AkzoNobel 467 13.036
Alfen 16 24.804
Allfunds Group 4 1.473
Almunda Professionals (vh Novisource) 651 4.251
Alpha Pro Tech 1 17
Alphabet Inc. 1 406
Altice 106 51.198
Alumexx ((Voorheen Phelix (voorheen Inverko)) 8.486 114.822
AM 228 684
Amarin Corporation 1 133
Amerikaanse aandelen 3.837 243.162
AMG 971 133.325
AMS 3 73
Amsterdam Commodities 305 6.689
AMT Holding 199 7.047
Anavex Life Sciences Corp 2 491
Antonov 22.632 153.605
Aperam 92 14.998
Apollo Alternative Assets 1 17
Apple 5 381
Arcadis 252 8.776
Arcelor Mittal 2.033 320.706
Archos 1 1
Arcona Property Fund 1 286
arGEN-X 17 10.300
Aroundtown SA 1 219
Arrowhead Research 5 9.737
Ascencio 1 27
ASIT biotech 2 697
ASMI 4.108 39.096
ASML 1.766 107.172
ASR Nederland 21 4.484
ATAI Life Sciences 1 7
Atenor Group 1 491
Athlon Group 121 176
Atrium European Real Estate 2 199
Auplata 1 55
Avantium 32 13.667
Axsome Therapeutics 1 177
Azelis Group 1 64
Azerion 7 3.392

Macro & Bedrijfsagenda

  1. 24 februari

    1. Vastned Q4-cijfers
    2. PostNL Q4-cijfers
    3. Ifo ondernemersvertrouwen februari (Dld)
    4. Inflatie januari def. (eur)
    5. Chicago Fed index januari (VS)
    6. Retail Estates Q3-cijfers
    7. Vastned Belgium Q4-cijfers
    8. Zoom Video Communications Q4-cijfers (VS)
  2. 25 februari

    1. Ackermans & Van Haaren Q4-cijfers
    2. Economische groei vierde kwartaal def (Dld)
de volitaliteit verwacht indicator betekend: Market moving event/hoge(re) volatiliteit verwacht